cisapride has been researched along with amodiaquine hydrochloride in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Abu Khalaf, R; Abu Sheikha, G; Bustanji, Y; Taha, MO | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Carbajo, RJ; Gozalbes, R; Melnyk, P; Mosulén, S; Ortí, L; Pineda-Lucena, A; Rodríguez-Díaz, J | 1 |
4 other study(ies) available for cisapride and amodiaquine hydrochloride
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Topics: Cholesterol Ester Transfer Proteins; Drug Discovery; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; ROC Curve | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Topics: Amodiaquine; Antimalarials; Binding Sites; Catalytic Domain; Drug Design; Glucuronidase; Humans; Ligands; Molecular Docking Simulation; Nuclear Magnetic Resonance, Biomolecular; Quantitative Structure-Activity Relationship; Recombinant Proteins; Structure-Activity Relationship | 2013 |